Patents by Inventor Steven David Knight

Steven David Knight has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 10604531
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Steven David Knight, Louis Vincent Lafrance, III, Xinrong Tian
  • Enhancer of Zeste Homolog 2 inhibitors
    Patent number: 10478426
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 19, 2019
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20190092785
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: May 1, 2017
    Publication date: March 28, 2019
    Inventors: Steven David KNIGHT, Louis Vincent LAFRANCE, III, Xinrong TIAN
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20180207144
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: March 20, 2018
    Publication date: July 26, 2018
    Inventors: Joelle Lorraine BURGESS, Steven David KNIGHT
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20180162845
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 30, 2016
    Publication date: June 14, 2018
    Inventors: James A. BRACKLEY, III, Alan Peterson GRAVES, III, Steven David KNIGHT, Kenneth C. MCNULTY, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9956210
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: December 15, 2016
    Date of Patent: May 1, 2018
    Assignee: GLAXOSMITHKLINE LLC
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170334891
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 28, 2015
    Publication date: November 23, 2017
    Applicant: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Steven David KNIGHT, Kenneth Allen NEWLANDER, Xinrong TIAN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9790212
    Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.
    Type: Grant
    Filed: October 13, 2016
    Date of Patent: October 17, 2017
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170095461
    Abstract: This invention relates to novel substituted benzamide according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: December 15, 2016
    Publication date: April 6, 2017
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9562041
    Abstract: This invention relates to novel substituted benzamides according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: May 15, 2013
    Date of Patent: February 7, 2017
    Assignee: GlaxoSmithKline LLC
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20170029412
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: October 13, 2016
    Publication date: February 2, 2017
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9556157
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: January 31, 2017
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Joelle Lorraine Burgess, Steven David Knight
  • Enhancer of zeste homolog 2 inhibitors
    Patent number: 9505745
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: April 25, 2014
    Date of Patent: November 29, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Charles William Blackledge, Jr., Joelle Lorraine Burgess, Neil W. Johnson, Jiri Kasparec, Steven David Knight, Louis V. LaFrance, III, Juan I. Luengo, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Mark Schulz, Dai-Shi Su, Xinrong Tian
  • Indoles
    Patent number: 9402836
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: August 2, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: James Brackley, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • Enhancer of Zeste Homolog 2 inhibitors
    Patent number: 9382234
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: December 12, 2013
    Date of Patent: July 5, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: Steven David Knight, William Henry Miller, Kenneth Allen Newlander, Carla A. Donatelli
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160130261
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: July 9, 2014
    Publication date: May 12, 2016
    Inventors: Joelle Lorraine BURGESS, Steven David KNIGHT
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160122342
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: June 6, 2014
    Publication date: May 5, 2016
    Inventors: David T. FOSBENNER, Bryan W. KING, Steven David KNIGHT, Louis Vincent LaFRANCE, III, Mei LI, Kenneth C. McNULTY, Stuart Paul ROMERIL, Mark Andrew SEEFELD
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20160102083
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: April 25, 2014
    Publication date: April 14, 2016
    Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Charles William BLACKLEDGE, JR., Joelle Lorraine BURGESS, Neil W. JOHNSON, Jiri KASPAREC, Steven David KNIGHT, Louis V. LaFRANCE, III, Juan I. LUENGO, William Henry MILLER, Kenneth Allen NEWLANDER, Stuart Paul ROMERIL, Mark SCHULZ, Dai-Shi SU, Xinrong TIAN
  • INDOLES
    Publication number: 20150313887
    Abstract: Herein are disclosed indoles of formula (I) where the various groups are defined herein, and which are useful for treating cancer.
    Type: Application
    Filed: July 9, 2015
    Publication date: November 5, 2015
    Inventors: James BRACKLEY, III, Joelle Lorraine Burgess, Seth Wilson Grant, Neil W. Johnson, Steven David Knight, Louis Vincent LaFrance, III, William Henry Miller, Kenneth Allen Newlander, Stuart Paul Romeril, Meagan B. Rouse, Xinrong Tian, Sharad Kumar Verma
  • ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS
    Publication number: 20150307480
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Application
    Filed: December 12, 2013
    Publication date: October 29, 2015
    Inventors: Steven David KNIGHT, William Henry MILLER, Kenneth Allen NEWLANDER, Carla A. DONATELLI